asco@alo33:161480 JSONTXT

Background: We previously reported that lo volume centers have higher inpatient mortality OR 3.26 than high-volume centers 3 inpatient chemotherapy CT month m hen delivering CT for patients pts ith AML Giri Blood 2015 . We hypothesized that an outcome-volume relationship ould also exist for high volume HVP versus lo volume providers LVP caring for pts ith Hodgkin lymphoma HL . Methods: After obtaining IRB approval e performed a retrospective chart revie of all pts treated ith ABVD for HL at the West Cancer Center from Jan 2010 to June 2015. Pts ere divided into HVP provider prescribing 3 CT per m and LVP lt 3 CT per m . EFS as defined as death from any cause or treatment failure, OS as death from any cause. All analyses ere performed using Microsoft Excel and GraphPad Prism. Results: 93 pts received at least one dose of CT. 21 pts ere cared for by a HVP and 72 by LVP range 1-9 pts delivering a mean of 3.3 and 0.8 doses of CT per month, respectively. While there ere more females in the HVP versus LVP 56 percent vs. 29 percent there ere no statistical differences in age, IPS hich includes gender or stage distribution beteen the HVP and LVP groups. Unfavorable risk 2B pts HVP 62 percent vs. LVP 57 percent, p = 0.803 ere also ell balanced. HVP ere less likely to cause total dose delays OR 0.32, CI 0.1584-0.6511, p = 0.0007 and to hold doses for afebrile neutropenia ANP OR 0.05, CI 0.0032-0.8509, p = 0.0006 . The toxic death rate as not statistically loer in the HVP group OR 0.18, CI 0.010-3.189, p = 0.1913 . HVP delivered significantly feer prophylactic groth factors 0 percent of doses vs. 42 percent, OR 0.00, CI lt 0.000-0.060, p lt 0.0001 . Both EFS HR 6.68, CI 1.103-7.626, p = 0.0321 and OS HR 3.68, CI 1.110-12.22, p = 0.032 ere significantly inferior in the LVP group. Conclusions: Pts ith HL treated by LVP may have orse outcomes compared to patients treated by HVP similar to hat e demonstrated for pts ith AML in LV centers. This may be explained in part by lack of familiarity ith the NCCN guidelines that lead to treatment delays for ANP and consequently loer dose-intensity.,J Clin Oncol 34, 2016 suppl; abstr e18203 ,Publication Only Health Services Research and Quality of Care